Compositions and methods for diagnosis and treatment for type 2 diabetes

• US 20080300170A1
• Filed: 09/18/2007
• Published: 12/04/2008
• Est. Priority Date: 09/01/2006
• Status: Abandoned Application

• Current Assignee: American Type Culture Collection
• Original Assignee: American Type Culture Collection
• Inventors: Ikonomi, Pranvera, Gelber, Cohava, Liu, Liping, Xie, Zhidong, Auge, Catherine R., Simms, John R.
• Application Number:
  US11/901,925
• Publication Number:
  US 20080300170A1
• Time in Patent Office: Days
• US Class Current: 514/3
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

Claims

1. A method of diagnosing or identifying type 2 Diabetes, one or more complications related to type 2 Diabetes, or a pre-diabetic condition in a subject, comprising:

a. measuring an effective amount of one or more T2DBMARKERS or a metabolite thereof in a sample from the subject; and

b. comparing the amount to a reference value, wherein an increase or decrease in the amount of the one or more T2DBMARKERS relative to the reference value indicates that the subject suffers from the type 2 Diabetes, one or more complications related to type 2 Diabetes, or the pre-diabetic condition.

2. The method of claim 1, wherein the reference value comprises an index value, a value derived from one or more Diabetes risk prediction algorithms or computed indices, a value derived from a subject not suffering from type 2 Diabetes or the pre-diabetic condition, a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes or the pre-diabetic condition, or a value derived from a subject previously diagnosed with or identified as suffering from one or more complications related to type 2 Diabetes.

3. The method according to claim 1, wherein the subject comprises one who has been previously diagnosed as having type 2 Diabetes, one or more complications related to type 2 Diabetes, or a pre-diabetic condition, one who has not been previously diagnosed as having type 2 Diabetes, one or more complications related to type 2 Diabetes, or a pre-diabetic condition, or one who is asymptomatic for the type 2 Diabetes, one or more complications related to type 2 Diabetes or a pre-diabetic condition.

15. A kit comprising T2DBMARKER detection reagents that detect one or more T2DBMARKERS, a sample derived from a subject having normal glucose levels, and optionally instructions for using the reagents in the method of any one of claims 1, 4, and 12, wherein the T2DBMARKER detection reagents comprise the isolated antibody of claim 17.

16. The kit of claim 15, wherein the detection reagents further comprise one or more antibodies or fragments thereof, one or more aptamers, one or more oligonucleotides, or combinations thereof.

4. A method for monitoring the progression of type 2 Diabetes, one or more complications relating to type 2 Diabetes, or a pre-diabetic condition in a subject, comprising

a. detecting an effective amount of one or more T2DBMARKERS in a first sample from the subject at a first period of time;

b. detecting an effective amount of one or more T2DBMARKERS in a second sample from the subject at a second period of time; and

c. comparing the amounts of the one or more T2DBMARKERS detected in step (a) to the amount detected in step (b), or to a reference value.

5. The method of claim 4, wherein the monitoring comprises evaluating changes in the risk of developing type 2 Diabetes, one or more complications relating to type 2 Diabetes, or the pre-diabetic condition.

6. The method of claim 4, wherein the subject comprises one who has previously been treated for the type 2 Diabetes, one or more complications relating to type 2 Diabetes, or the pre-diabetic condition, one who has not been previously treated for the type 2 Diabetes, one or more complications relating to type 2 Diabetes, or the pre-diabetic condition, or one who has not been previously diagnosed with or identified as suffering from type 2 Diabetes, one or more complications relating to type 2 Diabetes, or the pre-diabetic condition.

7. The method of claim 4, wherein the first sample is taken from the subject prior to being treated for the type 2 Diabetes, one or more complications relating to type 2 Diabetes, or the pre-diabetic condition.

8. The method of claim 4, wherein the second sample is taken from the subject after being treated for the type 2 Diabetes, one or more complications relating to type 2 Diabetes, or the pre-diabetic condition.

9. The method of claim 4, wherein the monitoring further comprises selecting a treatment regimen for the subject and/or monitoring the effectiveness of a treatment regimen for type 2 Diabetes, one or more complications relating to type 2 Diabetes, or the pre-diabetic condition.

10. The method of claim 9, wherein the treatment for the type 2 Diabetes, one or more complications relating to type 2 Diabetes, or the pre-diabetic condition comprises exercise regimens, dietary supplements, surgical intervention, diabetes-modulating agents, or combinations thereof.

11. The method of claim 4, wherein the reference value comprises an index value, a value derived from one or more Diabetes risk prediction algorithms or computed indices, a value derived from a subject not suffering from type 2 Diabetes, one or more complications relating to type 2 Diabetes, or a pre-diabetic condition, or a value derived from a subject diagnosed with or identified as suffering from type 2 Diabetes, one or more complications relating to type 2 Diabetes, or a pre-diabetic condition.

12. A method of treating a subject diagnosed with or identified as suffering from type 2 Diabetes, one or more complications relating to type 2 Diabetes, or a pre-diabetic condition comprising:

a. detecting an effective amount of one or more T2DBMARKERS or metabolites thereof present in a first sample from the subject at a first period of time; and

b. treating the subject with one or more diabetes-modulating agents until the amounts of the one or more T2DBMARKERS or metabolites thereof return to a reference value measured in one or more subjects at low risk for developing type 2 Diabetes, one or more complications relating to type 2 Diabetes, or a pre-diabetic condition, or a reference value measured in one or more subjects who show improvements in Diabetes risk factors as a result of treatment with the one or more diabetes-modulating agents.

13. The method of claim 12, wherein the one or more diabetes-modulating agents comprise sulfonylureas, biguanides, insulin, insulin analogs, peroxisome proliferator-activated receptor-γ

(PPAR-γ

) agonists, dual-acting PPAR agonists, insulin secretagogues, analogs of glucagon-like peptide-1 (GLP-1), inhibitors of dipeptidyl peptidase IV, pancreatic lipase inhibitors, α

-glucosidase inhibitors, or combinations thereof.

14. The method of claim 12, wherein the improvements in Diabetes risk factors as a result of treatment with one or more diabetes-modulating agents comprise a reduction in body mass index (BMI), a reduction in blood glucose levels, an increase in insulin levels, an increase in HDL levels, a reduction in systolic and/or diastolic blood pressure, or combinations thereof.

17. An isolated antibody or antigen-binding fragment thereof, comprising a human constant region and an antigen-binding region, wherein the antigen-binding region binds one or more T2DBMARKERS or a metabolite thereof.

18. The isolated antibody of claim 17, wherein the antigen-binding region binds one or more amino acid residues of SEQ ID NO:

1.

19. The isolated antibody of claim 17, which is recombinant.